Lundbeck’s acquisition of Longboard Pharmaceuticals aims to bolster its neuro-rare conditions portfolio with the addition of bexicaserin. Credit: UnderhilStudio/Shutterstock. Lundbeck has signed an agreement to acquire Longboard Pharmaceuticals for $2.6bn equity value in a move set to enhance its capabilities […]
Lundbeck to acquire Longboard Pharmaceuticals for $2.6bn Read More »
ENHERTU is indicated for patients with unresectable or metastatic NSCLC with activating HER2 mutations who have previously undergone systemic therapy. Credit: Nemes Laszlo/Shutterstock. Daiichi Sankyo and AstraZeneca‘s ENHERTU has been conditionally approved by China’s National Medical Products Administration (NMPA) as
ENHERTU gains conditional approval in China Read More »
The decision marks a significant step in Sanofi’s ongoing effort to sharpen its focus on its core areas of innovative medicines and vaccines. Credit: jd8/Shutterstock. Sanofi has announced negotiations with Clayton Dubilier & Rice (CD&R), a US-based investment company, regarding
Sanofi in talks to sell stake in consumer healthcare unit to CD&R Read More »
The FDA approval of HYMPAVZI was supported by the Phase III BASIS clinical trial. Credit: Andrey_Popov/Shutterstock. Pfizer has announced the approval of HYMPAVZI (marstacimab-hncq) by the US Food and Drug Administration (FDA) for routine prophylaxis in patients with haemophilia A
FDA approves Pfizer’s HYMPAVZI to treat haemophilia Read More »
